The U.S. Food and Drug Administration (FDA) has approved Firocoxib Tablets for Horses. To be marketed under the brand name Sē•Qual™, Firocoxib Tablets for Horses will be the first generic nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation associated with equine osteoarthritis, as well as the first generic pharmaceutical from Pegasus Labs, parent company of PRN® Pharmacal.
The first generic of the pioneer product known as Equioxx® by Boehringer-Ingelheim®, Firocoxib Tablets for Horses by Sē•Qual works by affecting certain enzymes that trigger pain, fever, and inflammation.
Firocoxib Tablets for Horses will be available in 60-count bottles as half-scored tablets in 57 mg of firocoxib to be administered once daily for up to 14 days. Available only by prescription, Firocoxib Tablets for Horses is currently in production and will be accessible to veterinarians and their customers by early September.
The Sē•Qual brand reflects Pegasus Labs’ commitment to quality manufacturing, while acknowledging that the generic products will be the second chapter (or “sequel”) to the pioneer drugs. Pegasus expects to launch its second generic pharmaceutical under the Sē•Qual label within the next six months.
Pegasus Laboratories was founded in 1986 and acquired by PBI-Gordon Corporation in 1999. A Contract Development and Manufacturing Organization, Pegasus produces animal health products, and distributes products under the PRN® Pharmacal brand name into the veterinary market. Pegasus Laboratories provides full turn-key technical services in a cGMP facility that is DEA-approved.